Pakistan, Sept. 9 -- The World Health Organization (WHO) has officially recommended the use of a new class of weight-loss drugs to treat obesity and diabetes globally. These drugs, known as GLP-1 agonists, include popular brands like Ozempic, Wegovy, and Mounjaro. WHO's endorsement marks the first time these medications have been acknowledged as essential for treating obesity, which affects millions worldwide.

The growing popularity of GLP-1 drugs is due to their ability to significantly aid weight loss, with some users shedding substantial amounts of weight. However, despite their effectiveness, the high costs of these medications remain a major barrier. In the U.S., for example, these drugs can exceed $1,000 per month, making them unaf...